Amgen Inc.

Initial read: the operating transition is working; at approximately $377 the stock looks closer to fairly valued than cheap. Amgen is a portfolio-replacement story, not a Tavneos or Lp(a) binary.

1. Seven visible growth franchises—Repatha, Evenity, Tepezza, Krystexxa, Uplizna, Tezspire and Imdelltra—added approximately $1.03 billion of quarterly sales year on year in 2Q26. Prolia and Xgeva lost $543 million, while Otezla, Kyprolis and MVASI lost another $229 million.
2. That replacement arithmetic works today. The question is whether it still works after current growth rates normalize and the denosumab erosion curve matures.
3. Amgen's own six-driver statistic requires care: it comprises three products—Repatha, Evenity and Tezspire—and three portfolio categories—Rare Disease, Innovative Oncology and Biosimilars. Together they represented nearly 70% of product sales and grew 26%, but Rare Disease contains assets with different growth quality and Innovative Oncology includes declining Kyprolis while excluding Xgeva.
4. Revenue growth is real; earnings growth is expensive. Total revenue increased 10% to $10.1 billion and product sales grew 9% on volume, but non-GAAP EPS rose only 4% and non-GAAP operating margin declined 50 basis points to 48.4%.
5. Non-GAAP cost of sales reached 19.6% of product sales on higher profit-sharing and royalty expense, manufacturing cost and mix; non-GAAP R&D rose 10% as Amgen funded nine global Phase 3 MariTide studies, with a further $100 million business-development upfront expected in 3Q R&D. The transition is being funded rather than arriving as free operating leverage.
6. The erosion is also reported, not forecast. Prolia declined 32% on 20% lower volume and 12% lower net price; Xgeva declined 34%; Otezla fell 21% on both volume and price pressure.
7. Enbrel's underlying net price declined 22% before favorable changes to estimated sales deductions. Against that, Repatha and Evenity remain volume-led and underpenetrated, while Uplizna's early gMG mix—roughly even between biologic-naive and switching patients—and sequential doubling of U.S. prescribers support a broader multi-indication franchise.
8. Imdelltra is now the most credible nearer-term value addition. The product converted to FDA traditional approval in November 2025, removing the confirmatory-evidence overhang from the existing post-platinum franchise.
9. DeLLphi-305 then met overall survival at a prespecified interim analysis in 563 randomized patients, with PFS and ORR also positive. U.S. monitoring after the first two doses was reduced to one to two hours in this trial, versus six to eight hours in certain regions including Europe, making community-adoption risk regional rather than universal.
10. A preliminary U.S. maintenance funnel of roughly 17,000–19,000 eligible patients and 35–50% peak penetration supports a multi-billion-dollar worldwide scenario, but the hazard ratio, PFS curve, treatment duration and detailed safety remain necessary before tightening it. Leverage constrains rather than threatens: June cash was $14.0 billion against $57.3 billion of debt, debt was up $2.7 billion from year-end, and management did not provide a new aggressive deleveraging target.
11. At the September 11 close, equity value was approximately $204 billion, enterprise value approximately $247 billion and the shares traded near 16.5x the midpoint of 2026 non-GAAP EPS guidance. The 4–11 September close-to-close decline removed approximately $32 billion of equity value; the drawdown from the $447.03 52-week high was closer to $38 billion.
12. That repricing appears disproportionate to a long-dated olpasiran read-through and Tavneos, but it does not make the remaining valuation distressed. Tavneos is an impaired but contained franchise at roughly 1.5% of quarterly product sales.
13. Olpasiran is a potentially large cardiovascular option whose probability was reduced, not resolved, by pelacarsen's HORIZON miss; the asset-level probability belongs in the linked research note and should not define the company thesis.